Long-term death and recurrence in patients with acute venous thromboembolism: The MASTER registry

Background: The long-termclinical outcome of VTE has been essentially assessed in cohorts of selected patients. The aim of thismulticenter registry was to prospectively assess the long-term clinical outcome in a cohort of unselected patients with objectively confirmed acute VTE. Materials and Methods: Death and VTE recurrence at 24 months were the main study outcomes. Univariate and multivariate survival analyses were performed according to the Kaplan-Meyer and Cox proportional hazard model, respectively. Results: 2119 patients with acute VTE were included in the registry: 1541 (72.7%) with deep vein thrombosis, 206 (9.7%) with pulmonary embolism and 372 (17.6%) with both. Information about death was available in 2021 patients (95.4%) and about recurrence in 1988 patients (93.8%). 167 patients (4.55% patient-year) died during follow-up. After adjusting for age, cancer (Hazard ratio [HR]: 7.2; 95% CI 4.8-10.8), long-term heparin treatment (HR: 2.5; 95% CI 1.8-3.5), in-hospital management of VTE (HR: 2.0; 95% CI 1.3-3.0), and ileo-caval thrombosis (HR: 1.7; 95% CI 1.2-2.4) were found to be independent predictors of death. 124 (3.63% patient-year) patients had a VTE recurrence during follow-up. In-hospital management of VTE (HR: 1.8; 95% CI 1.2-2.9), male gender (HR: 1.7; 95% CI 1.2-2.4) were independent risk factors for recurrent VTE. Cancer (HR: 1.6; 95% CI 1.0-2.8) showed a trend for increased risk of VTE recurrence (p=0.056). The reported rate of major bleeding was 2.5%. Conclusions: In a large cohort of unselected VTE patients, cancer, ileo-caval thrombosis, long-term heparin treatment and in-hospital management were associated with increased mortality during long-term follow-up. In-hospital management, male gender were associated with an increased risk of VTE recurrence. (C) 2012 Elsevier Ltd. All rights reserved.